Myung G. Lee

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

23h-index2.5kcitations164works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(104), Drug Transport and Resistance Mechanisms(84), Pharmacological Effects and Toxicity Studies(40), Antibiotics Pharmacokinetics and Efficacy(38), Drug-Induced Hepatotoxicity and Protection(22)

Publications164 total

Does Comparable Accounting Information Reduce Valuation Errors?
Review of Accounting and Policy Studies·2020
Pharmacokinetic and pharmacodynamic interaction between nifedipine and metformin in rats: competitive inhibition for metabolism of nifedipine and metformin by each other via CYP isozymes
Xenobiotica·2012· 23 cited
Pharmacokinetics of mirodenafil and Its two metabolites, SK3541 and SK3544, in spontaneously or DOCA–salt‐induced hypertensive rats
Biopharmaceutics & Drug Disposition·2010· 4 cited
Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats
Journal of Pharmacy and Pharmacology·2010· 14 citedOpen Access
Dose‐dependent pharmacokinetics of SP‐8203 in rats
Biopharmaceutics & Drug Disposition·2010· 3 cited
Liquiritigenin pharmacokinetics in a rat model of diabetes mellitus induced by streptozotocin: greater formation of glucuronides in the liver, especially M2, due to increased hepatic uridine 5′-diphosphoglucuronic acid level
Metabolism·2010· 12 cited
Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus
Journal of Pharmacy and Pharmacology·2010· 111 citedOpen Access
Pharmacokinetic interaction between liquiritigenin (LQ) and DDB: Increased glucuronidation of LQ in the liver possibly due to increased hepatic blood flow rate by DDB
European Journal of Pharmaceutical Sciences·2009· 7 cited
Effect of hepatic CYP inhibitors on the metabolism of sildenafil and formation of its metabolite,<i>N</i>-desmethylsildenafil, in rats<i>in vitro</i>and<i>in vivo</i>
Journal of Pharmacy and Pharmacology·2009· 9 citedOpen Access
Effect of hepatic CYP inhibitors on the metabolism of sildenafil and formation of its metabolite, &lt;I&gt;N&lt;/I&gt;-desmethylsildenafil, in rats &lt;I&gt;in vitro&lt;/I&gt; and &lt;I&gt;in vivo&lt;/I&gt;
Journal of Pharmacy and Pharmacology·2009· 14 cited
Faster clearance of mirodenafil in rats with acute renal failure induced by uranyl nitrate: contribution of increased protein expression of hepatic CYP3A1 and intestinal CYP1A1 and 3A1/2
Journal of Pharmacy and Pharmacology·2009· 10 cited
Faster clearance of mirodenafil in rats with acute renal failure induced by uranyl nitrate: contribution of increased protein expression of hepatic CYP3A1 and intestinal CYP1A1 and 3A1/2
Journal of Pharmacy and Pharmacology·2009
Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin
European Journal of Pharmaceutical Sciences·2009· 16 cited
Time‐dependent effects of<i>Klebsiella pneumoniae</i>endotoxin on the pharmacokinetics of chlorzoxazone and its main metabolite, 6‐hydroxychlorzoxazone, in rats: restoration of the parameters in 96 hour in KPLPS rats to control levels
Biopharmaceutics & Drug Disposition·2009· 2 cited
Dose‐dependent pharmacokinetics and first‐pass effects of mirodenafil, a new erectogenic, in rats
Biopharmaceutics & Drug Disposition·2009· 17 cited
Ipriflavone pharmacokinetics in mutant Nagase analbuminemic rats
Biopharmaceutics & Drug Disposition·2009· 3 cited
Slower clearance of intravenous metformin in rats with acute renal failure induced by uranyl nitrate: Contribution of slower renal and non-renal clearances
European Journal of Pharmaceutical Sciences·2009· 11 cited
Faster clearance of omeprazole in mutant Nagase analbuminemic rats: possible roles of increased protein expression of hepatic CYP1A2 and lower plasma protein binding
Biopharmaceutics & Drug Disposition·2009· 7 cited
Pharmacokinetics of Liquiritigenin in Mice, Rats, Rabbits, and Dogs, and Animal Scale-Up
Journal of Pharmaceutical Sciences·2009· 34 cited
Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism
Journal of Pharmacy and Pharmacology·2009· 21 cited
page 1 of 9Next →

Frequent Co-authors

Win L. Chiou(9), Young Hee Choi(8), Sang G. Kim(7), Joo H. Lee(6), Jong Won Kwon(6), Won B. Kim(6), Inchul Lee(6), So H. Kim(6), Soo Kyung Bae(6), So H. Kim(5), Yoon G. Kim(4), Eun J. Kim(4), Yu C. Kim(3), Sun H. Lee(3), Hyun Joo Shim(3), Mei‐Ling Chen(3), Young C. Kim(3), Kyung Yang(3), Dae Y. Lee(3), Young Choi(2)